Literature DB >> 18771343

Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

Gerald L DeNardo1, Sally J DeNardo, Rod Balhorn.   

Abstract

The cytocidal potency of a molecule can be augmented by conjugating a radionuclide for molecular targeted radionuclide therapy (MTRT) for cancer. Radioimmunotherapy (RIT) should be incorporated into the management of patients with B-cell non-Hodgkin's lymphoma (NHL) soon after the patients have proven incurable. Better drugs, strategies, and combinations with other drugs seem certain to make RIT integral to the management of patients with NHL and likely to lead to a cure of the currently incurable NHL. These improved drugs, strategies, and combinations thereof also offer opportunities for RIT to become part of the management of solid malignancies, including epithelial cancers. Smaller radionuclide carriers, such as those used for pretargeted strategies, provide dose intensification. The potential of pretargeted RIT to improve patient outcomes is striking.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18771343      PMCID： PMC2988689          DOI： 10.1089/cbr.2007.0523-U

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN： 1084-9785            Impact factor:   3.099


  79 in total

1.  Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.

Authors:  S J DeNardo; E L Kramer; R T O'Donnell; C M Richman; Q A Salako; S Shen; M Noz; S D Glenn; R L Ceriani; G L DeNardo
Journal:  J Nucl Med       Date:  1997-08       Impact factor: 10.057

2.  Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation.

Authors:  Michael R Zalutsky
Journal:  J Nucl Med       Date:  2006-08       Impact factor: 10.057

Review 3.  Pretargeted radioimmunotherapy of cancer: progress step by step.

Authors:  Otto C Boerman; Frank G van Schaijk; Wim J G Oyen; Frans H M Corstens
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

4.  Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.

Authors:  A Goel; S Augustine; J Baranowska-Kortylewicz; D Colcher; B J Booth; G Pavlinkova; M Tempero; S K Batra
Journal:  Clin Cancer Res       Date:  2001-01       Impact factor: 12.531

5.  Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

Authors:  Marion de Jong; Wout A P Breeman; Roelf Valkema; Bert F Bernard; Eric P Krenning
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

6.  64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.

Authors:  C J Anderson; F Dehdashti; P D Cutler; S W Schwarz; R Laforest; L A Bass; J S Lewis; D W McCarthy
Journal:  J Nucl Med       Date:  2001-02       Impact factor: 10.057

7.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Authors:  Thomas E Witzig; Leo I Gordon; Fernando Cabanillas; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Brad L Pohlman; Nancy L Bartlett; Gregory A Wiseman; Norman Padre; Antonio J Grillo-López; Pratik Multani; Christine A White
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

8.  The radioisotope contributes significantly to the activity of radioimmunotherapy.

Authors:  Thomas A Davis; Mark S Kaminski; John P Leonard; Frank J Hsu; Mary Wilkinson; Andrew Zelenetz; Richard L Wahl; Stewart Kroll; Morton Coleman; Michael Goris; Ronald Levy; Susan J Knox
Journal:  Clin Cancer Res       Date:  2004-12-01       Impact factor: 12.531

9.  The biologic window for chimeric L6 radioimmunotherapy.

Authors:  S J DeNardo; G R Mirick; L A Kroger; L F O'Grady; K L Erickson; A Yuan; K R Lamborn; I Hellstrom; K E Hellstrom; G L DeNardo
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

10.  Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.

Authors:  Andres Forero; Paul L Weiden; Julie M Vose; Susan J Knox; Albert F LoBuglio; Jordan Hankins; Michael L Goris; Vincent J Picozzi; Don B Axworthy; Hazel B Breitz; Robert B Sims; Richard G Ghalie; Sui Shen; Ruby F Meredith
Journal:  Blood       Date:  2004-03-02       Impact factor: 22.113
View more
  3 in total

1.  Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.

Authors:  Yuni K Dewaraja; Matthew J Schipper; Jincheng Shen; Lauren B Smith; Jure Murgic; Hatice Savas; Ehab Youssef; Denise Regan; Scott J Wilderman; Peter L Roberson; Mark S Kaminski; Anca M Avram
Journal:  J Nucl Med       Date:  2014-05-19       Impact factor: 10.057

2.  Pretargeted radioimmunotherapy for hematologic and other malignancies.

Authors:  Roland B Walter; Oliver W Press; John M Pagel
Journal:  Cancer Biother Radiopharm       Date:  2010-04       Impact factor: 3.099

3.  (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.

Authors:  Kwon Joong Yong; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  Mol Cancer Ther       Date:  2012-01-11       Impact factor: 6.261
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.